Atopic dermatitis (AD) is a common inflammatory skin disease with high prevalence both in children (15-30%) and adults (2-10%); limited data are available for the elderly. Elderly patients are challenging showing frequent multiple comorbidities, associated polypharmacy, and common previously treatments failure. We performed a retrospective observational study on elderly (≥ 65 year-old) patients treated with dupilumab, monoclonal antibody to the shared alpha subunit of the IL4 and IL-13 receptor approved for the treatment of moderate-to-severe AD in adults.
Efficacy and safety of dupilumab in atopic dermatitis of the elderly: A retrospective study / Napolitano, M; Fabbrocini, G; Scalvenzi, M; Blasio, C; Stingeni, L; Patruno, C. - In: CLINICAL AND EXPERIMENTAL DERMATOLOGY. - ISSN 0307-6938. - (2020). [10.1111/ced.14260]
Efficacy and safety of dupilumab in atopic dermatitis of the elderly: A retrospective study
Napolitano, M;Fabbrocini, G;Scalvenzi, M;Blasio, C;Patruno, C
2020
Abstract
Atopic dermatitis (AD) is a common inflammatory skin disease with high prevalence both in children (15-30%) and adults (2-10%); limited data are available for the elderly. Elderly patients are challenging showing frequent multiple comorbidities, associated polypharmacy, and common previously treatments failure. We performed a retrospective observational study on elderly (≥ 65 year-old) patients treated with dupilumab, monoclonal antibody to the shared alpha subunit of the IL4 and IL-13 receptor approved for the treatment of moderate-to-severe AD in adults.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
